Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [Therapy of untreated local advanced or metastatic renal cell carcinoma. Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic renal cell carcinoma (CheckMate 214

Literature DB >> 26350358

[Therapy of untreated local advanced or metastatic renal cell carcinoma. Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic renal cell carcinoma (CheckMate 214 - AN 36/15 of the AUO)].

H Rexer¹.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2015 PMID： 26350358 DOI： 10.1007/s00120-015-3946-5

Source DB: PubMed Journal: Urologe A ISSN： 0340-2592 Impact factor: 0.639

× No keyword cloud information.

6 in total

1. Improved survival with ipilimumab in patients with metastatic melanoma.

Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245

2. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.

Authors: Robert J Motzer; Thomas E Hutson; Lauren McCann; Keith Deen; Toni K Choueiri
Journal: N Engl J Med Date: 2014-05-01 Impact factor: 91.245

3. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.

Authors: Robert J Motzer; Carlos H Barrios; Tae Min Kim; Silvia Falcon; Thomas Cosgriff; W Graydon Harker; Vichien Srimuninnimit; Ken Pittman; Roberto Sabbatini; Sun Young Rha; Thomas W Flaig; Ray Page; Sevil Bavbek; J Thaddeus Beck; Poulam Patel; Foon-Yiu Cheung; Sunil Yadav; Edward M Schiff; Xufang Wang; Julie Niolat; Dalila Sellami; Oezlem Anak; Jennifer J Knox
Journal: J Clin Oncol Date: 2014-07-21 Impact factor: 44.544

Review 4. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma.

Authors: Manuela Schmidinger; Joaquim Bellmunt
Journal: Cancer Treat Rev Date: 2010-02-16 Impact factor: 12.111

5. Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Authors: Robert J Motzer; Thomas E Hutson; David Cella; James Reeves; Robert Hawkins; Jun Guo; Paul Nathan; Michael Staehler; Paul de Souza; Jaime R Merchan; Ekaterini Boleti; Kate Fife; Jie Jin; Robert Jones; Hirotsugu Uemura; Ugo De Giorgi; Ulrika Harmenberg; Jinwan Wang; Cora N Sternberg; Keith Deen; Lauren McCann; Michelle D Hackshaw; Rocco Crescenzo; Lini N Pandite; Toni K Choueiri
Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245

6. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

Authors: Suzanne L Topalian; Mario Sznol; David F McDermott; Harriet M Kluger; Richard D Carvajal; William H Sharfman; Julie R Brahmer; Donald P Lawrence; Michael B Atkins; John D Powderly; Philip D Leming; Evan J Lipson; Igor Puzanov; David C Smith; Janis M Taube; Jon M Wigginton; Georgia D Kollia; Ashok Gupta; Drew M Pardoll; Jeffrey A Sosman; F Stephen Hodi
Journal: J Clin Oncol Date: 2014-03-03 Impact factor: 44.544

6 in total

16 in total

Review 1. Immunotherapy in lung cancer.

Authors: Erminia Massarelli; Vassiliki Papadimitrakopoulou; James Welsh; Chad Tang; Anne S Tsao
Journal: Transl Lung Cancer Res Date: 2014-02

Review 2. The emergence of nanoporous materials in lung cancer therapy.

Authors: Deepika Radhakrishnan; Shan Mohanan; Goeun Choi; Jin-Ho Choy; Steffi Tiburcius; Hoang Trung Trinh; Shankar Bolan; Nikki Verrills; Pradeep Tanwar; Ajay Karakoti; Ajayan Vinu
Journal: Sci Technol Adv Mater Date: 2022-07-20 Impact factor: 7.821

Review 3. Current and future systemic treatment options in metastatic pancreatic cancer.

Authors: Cagatay Arslan; Suayib Yalcin
Journal: J Gastrointest Oncol Date: 2014-08

4. Launch of Breakthrough Therapies Will Reshape Renal Cell Carcinoma Market.

Authors: Chris Fellner
Journal: P T Date: 2016-08

Review 5. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies.

Authors: Huijuan Cheng; Guodong Sun; Hao Chen; Yu Li; Zhijian Han; Yangbing Li; Peng Zhang; Luxi Yang; Yumin Li
Journal: Am J Cancer Res Date: 2019-08-01 Impact factor: 6.166

1. Improved survival with ipilimumab in patients with metastatic melanoma.

2. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.

3. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.

Review 4. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma.

5. Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

6. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

Review 1. Immunotherapy in lung cancer.

Review 2. The emergence of nanoporous materials in lung cancer therapy.

Review 3. Current and future systemic treatment options in metastatic pancreatic cancer.

4. Launch of Breakthrough Therapies Will Reshape Renal Cell Carcinoma Market.

Review 5. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies.

Review 6. Contemporary Treatment of Metastatic Renal Cell Carcinoma.

Review 7. New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy.

Review 8. Immune Checkpoint in Glioblastoma: Promising and Challenging.

Review 9. Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma.

Review 10. Rational combinations of immunotherapeutics that target discrete pathways.